BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34027585)

  • 1. Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.
    Chopra A; Zenati M; Hogg ME; Zeh HJ; Bartlett DL; Bahary N; Zureikat AH; Beane JD
    Ann Surg Oncol; 2021 Nov; 28(12):7759-7769. PubMed ID: 34027585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.
    Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of additional therapy for residual pancreatic cancer.
    Yamada S; Sonohara F; Tashiro M; Murotani K; Takami H; Hayashi M; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujii T; Kodera Y
    Surg Today; 2020 May; 50(5):440-448. PubMed ID: 31650262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
    Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
    Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma.
    Crippa S; Giannone F; Schiavo Lena M; Belfiori G; Partelli S; Tamburrino D; Delpini R; Pagnanelli M; Pecorelli N; Balzano G; Doglioni C; Falconi M
    Ann Surg Oncol; 2021 Aug; 28(8):4602-4612. PubMed ID: 33393031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment.
    Leonhardt CS; Pils D; Qadan M; Jomrich G; Assawasirisin C; Klaiber U; Sahora K; Warshaw AL; Ferrone CR; Schindl M; Lillemoe KD; Strobel O; Fernández-Del Castillo C; Hank T
    Ann Surg; 2024 Feb; 279(2):314-322. PubMed ID: 37042245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery.
    Tummers WS; Groen JV; Sibinga Mulder BG; Farina-Sarasqueta A; Morreau J; Putter H; van de Velde CJ; Vahrmeijer AL; Bonsing BA; Mieog JS; Swijnenburg RJ
    Br J Surg; 2019 Jul; 106(8):1055-1065. PubMed ID: 30883699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
    Ghaneh P; Kleeff J; Halloran CM; Raraty M; Jackson R; Melling J; Jones O; Palmer DH; Cox TF; Smith CJ; O'Reilly DA; Izbicki JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Padbury R; Shannon J; Dervenis C; Glimelius B; Deakin M; Anthoney A; Lerch MM; Mayerle J; Oláh A; Rawcliffe CL; Campbell F; Strobel O; Büchler MW; Neoptolemos JP;
    Ann Surg; 2019 Mar; 269(3):520-529. PubMed ID: 29068800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
    Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
    JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
    Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
    Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
    Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
    Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant Chemotherapy.
    Hank T; Sandini M; Ferrone CR; Rodrigues C; Weniger M; Qadan M; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    JAMA Surg; 2019 Oct; 154(10):943-951. PubMed ID: 31411659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
    Sekigami Y; Michelakos T; Fernandez-Del Castillo C; Kontos F; Qadan M; Wo JY; Harrison J; Deshpande V; Catalano O; Lillemoe KD; Hong TS; Ferrone CR
    Ann Surg Oncol; 2021 Aug; 28(8):4592-4601. PubMed ID: 33393047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
    Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM
    Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis.
    Leonhardt CS; Hank T; Pils D; Gustorff C; Sahora K; Schindl M; Verbeke CS; Strobel O; Klaiber U
    Int J Surg; 2024 Jan; 110(1):453-463. PubMed ID: 38315795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of resection margin status on recurrence pattern and survival in distal pancreatectomy for left-sided pancreatic ductal adenocarcinoma.
    Kwon J; Lee SR; Park SY; Lee JH; Song KB; Hwang DW; Shin JH; Kim SC
    J Hepatobiliary Pancreat Sci; 2023 May; 30(5):633-643. PubMed ID: 36380718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.
    Depypere L; Moons J; Lerut T; De Hertogh G; Peters C; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Dis Esophagus; 2018 Feb; 31(2):. PubMed ID: 29036407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
    Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
    JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of margin status determined by the one-millimeter rule on tumor recurrence and survival following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Nitta T; Nakamura T; Mitsuhashi T; Asano T; Okamura K; Tsuchikawa T; Tamoto E; Murakami S; Noji T; Kurashima Y; Ebihara Y; Nakanishi Y; Shichinohe T; Hirano S
    Surg Today; 2017 Apr; 47(4):490-497. PubMed ID: 27677294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
    Lee SH; Hwang DW; Yoo C; Kim KP; Kang S; Jeong JH; Oh D; Song TJ; Lee SS; Park DH; Seo DW; Park JH; Song KB; Lee JH; Lee W; Park Y; Kwak BJ; Chang HM; Ryoo BY; Kim SC
    Cancer Res Treat; 2023 Jul; 55(3):956-968. PubMed ID: 36915253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.